Big growth in human challenge trials
This leader in the testing of infectious diseases using human challenge studies has reported excellent full year results. With a highly supportive order book, strong cash position and move to a larger and much improved facility, the future looks bright for our Stonking Small Cap.
Human Challenge Trials (HCTs), in which healthy volunteers are deliberately infected with a pathogen to study the course of a disease and the effectiveness of potential treatments, are a valuable tool for developing new vaccines and treatments for infectious diseases. The fast-growing AIM company covered below is developing a leading position in HCTs and has recently announced excellent interim results. It provides end-to-end early clinical development services for a broad and long-standing client base of global biopharma companies. Find out more about this exciting small company below, whose valuation also looks modest on many levels. AIM listed hVIVO (AIM:HVO), which was…